{"generic":"Carglumic Acid","drugs":["Carbaglu","Carglumic Acid"],"mono":{"0":{"id":"929604-s-0","title":"Generic Names","mono":"Carglumic Acid"},"1":{"id":"929604-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929604-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Hyperammonemia, type III, Acute treatment; Adjunct:<\/b> Initial, 100 to 250 mg\/kg\/day divided into 2 to 4 doses and rounded to the nearest 100 mg; disperse in water and give ORALLY or through NG TUBE immediately before meals or feedings; titrate based on plasma ammonia levels and clinical symptoms<\/li><li><b>Hyperammonemia, type III, Chronic treatment:<\/b> Individualize to achieve the target normal plasma ammonia level based on patient age; divide total daily dose into 2 to 4 doses and round to the nearest 100 mg; disperse in water and give ORALLY or through NG TUBE immediately before a meal or feeding.<\/li><\/ul>"},"1":{"id":"929604-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Hyperammonemia, type III, Acute treatment; Adjunct:<\/b> Initial, 100 to 250 mg\/kg\/day divided into 2 to 4 doses; disperse in water and give ORALLY or through NG TUBE immediately before meals or feedings; titrate based on plasma ammonia levels and clinical symptoms<\/li><li><b>Hyperammonemia, type III, Chronic treatment:<\/b> Individualize to achieve the target normal plasma ammonia level based on patient age; divide total daily dose into 2 to 4 doses, disperse in water and give ORALLY or through NG TUBE immediately before a meal or feeding.<\/li><\/ul>"},"3":{"id":"929604-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Hyperammonemia, type III, Acute treatment; Adjunct<\/li><li>Hyperammonemia, type III, Chronic treatment<\/li><\/ul>"}}},"3":{"id":"929604-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929604-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"929604-s-3-10","title":"Precautions","mono":"<ul><li>Endocrine and Metabolic:<\/li><li>-- Acute symptomatic hyperammonemia may occur, including possible brain injury or death; preventative therapy (complete protein restriction) and ongoing monitoring recommended<\/li><\/ul>"},{"id":"929604-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929604-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929604-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (17%), Diarrhea (13%), Vomiting (26%)<\/li><li><b>Hematologic:<\/b>Anemia (13%), Decreased hemoglobin (13%)<\/li><li><b>Neurologic:<\/b>Headache (13%)<\/li><li><b>Otic:<\/b>Infection of ear (13%)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (13%), Tonsillitis (17%)<\/li><li><b>Other:<\/b>Fever (17%), Infectious disease (13%)<\/li><\/ul>"},"6":{"id":"929604-s-6","title":"Drug Name Info","sub":{"0":{"id":"929604-s-6-17","title":"US Trade Names","mono":"Carbaglu<br\/>"},"3":{"id":"929604-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929604-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929604-s-7","title":"Mechanism Of Action","mono":"Carglumic acid, a synthetic analogue of N-acetylglutamate (NAG), activates carbomoyl phosphate synthetase-1 in hepatic mitochondria which allows for the conversion of ammonia to urea.<br\/>"},"8":{"id":"929604-s-8","title":"Pharmacokinetics","sub":[{"id":"929604-s-8-23","title":"Absorption","mono":"Tmax, Oral: 3 hr <br\/>"},{"id":"929604-s-8-24","title":"Distribution","mono":"Vd: 2657 L <br\/>"},{"id":"929604-s-8-25","title":"Metabolism","mono":"Intestinal bacteria <br\/>"},{"id":"929604-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 60% unchanged<\/li><li>Renal: 4.5% to 9% unchanged<\/li><li>Renal clearance: 290 mL\/minute<\/li><li>Total body clearance: 5.7 L\/minute<\/li><\/ul>"},{"id":"929604-s-8-27","title":"Elimination Half Life","mono":"5.6 hr <br\/>"}]},"9":{"id":"929604-s-9","title":"Administration","mono":"<ul><li><b>Nasogastric<\/b><br\/><ul><li>(Adults) Immediately before administration, mix each tablet with at least 2.5 mL of water and shake gently.<\/li><li>(Pediatrics) Immediately before administration, mix each tablet with at least 2.5 mL of water to a concentration of 80 mg\/mL and shake gently.<\/li><li>Administer immediately before a feeding.<\/li><li>(Adults) Immediately after preparation, administer through a NG tube and flush with additional water.<\/li><li>(Pediatrics) Immediately after preparation, draw the appropriate volume, administer through a NG tube, and flush with additional water; discard unused portion.<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>(Adults) Immediately before administration, disperse each tablet in at least 2.5 mL of water; Do not mix in other foods or liquids besides water.<\/li><li>(Pediatrics) Immediately before administration, mix each tablet with at least 2.5 mL of water to a concentration of 80 mg\/mL and shake gently.<\/li><li>Do not crush or swallow tablets whole.<\/li><li>Administer immediately before a meal.<\/li><li>(Adults) Administer immediately after preparation. Rinse mixing container with water and administer remaining contents (including undissolved portion of tablets).<\/li><li>(Pediatrics) Immediately after preparation, draw the appropriate volume in an oral syringe and administer; discard the unused portion. Refill the oral syringe with at least 1 to 2 mL of water and administer immediately.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929604-s-10","title":"Monitoring","mono":"<ul><li>Normalization of plasma ammonia level for age is indicative of clinical response<\/li><li>Plasma ammonia levels; during treatment<\/li><li>Neurologic status; on an ongoing basis<\/li><\/ul>"},"11":{"id":"929604-s-11","title":"How Supplied","mono":"<b>Carbaglu<\/b><br\/>Oral Tablet: 200 MG<br\/>"},"13":{"id":"929604-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to take all drugs that are prescribed for their hyperammonemia.<\/li><li>This drug may cause abdominal pain, pyrexia, tonsillitis, and vomiting.<\/li><li>Patient should disperse 200-mg tablet in a minimum of 2.5 mL of water and drink immediately. Additional water should be added to mixing container for any residual medicine and the contents ingested immediately.<\/li><li>Instruct patient to mix only with water and not with other liquids or food.<\/li><li>Advise patient to adhere to restrictions in protein intake, until instructed otherwise.<\/li><\/ul>"}}}